Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS.

What the trial testedrandomised · 2022

Randomised comparison

+5.80percentage points+3.40 to +8.30

As reported

difference 5.8 %, 95% CI 3.40–8.30

Randomised comparison

+4.40percentage points+1.30 to +9.90

As reported

difference 4.4 %, 95% CI 1.30–9.90

the abstract, start to end

Over 6 years, IL-6 increased by 5.8% (95% CI 3.4, 8.3) in the …

… percentage difference vs. placebo 4.4% [95% CI 1.3, 9.9; P = 0.01]).

← favours treatmentfavours comparator →

could be chance

Inflammation & biomarkers

5.83.40–8.30

Inflammation & biomarkers

4.41.30–9.90

SGLT2 inhibitorsInflammation & biomarkers

SGLT2 inhibitors × inflammation & biomarkershelps?mixed

unlikelylikely

0.500.96 without it

← favours treatmentfavours comparator →

this papermore certainless certain

1 / 5

2022

2023

2024

2025

2026

this paperpooled ittrialcites it